Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Elucidating the molecular mechanisms underlying relapse in acute myeloid leukemia

FY 2017-18

Summary
The hematopoietic (blood) system and all of its cellular components are generated by hematopoietic stem cells (HSCs). However, when the DNA of these HSCs becomes mutated, normal blood development goes awry and a form of blood cancer termed leukemia may arise. In acute myeloid leukemia (AML) patients initially diagnosed respond well to chemotherapy and achieve remission (a state where little to no detectable disease remains), however, many patients die from a more aggressive relapse disease that later recurs. Thus, a better understanding of how mutated HSCs and the cells they produce, behave over the entire disease course is necessary to improve dismal patient outcomes.Recently it was shown that different types of rare stem-like cells that are already present at diagnosis, survive chemotherapy and regenerate relapse. I reason that these different stem cell types must use different biological mechanisms to escape therapy and reestablish disease. By extension, patients would benefit from tailoring their therapy to the type of relapse they will experience.In this proposal I aim to use state-of-the-art genetic and protein analysis tools to investigate patient samples over the entire disease course. The highly sensitive approach will reveal biological mechanisms and molecules (biomarkers) unique to each relapse type. Novel insights into relapse and the biomarkers generated will be used to predict relapse type from a diagnostic sample and to monitor patients during remission in order to inform the future of improved and personalized patient care.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386495
Name
Medeiros Jessie J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the molecular mechanisms underlying relapse in acute myeloid leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Biomarkers; Clonal Heterogeneity; Genomics; Hematopoeisis; Hematopoietic And Leukemic Stem Cells; Leukemogenesis; Proteomics; Stem Cell Biology; Therapeutic Intervention
Abstract
The hematopoietic (blood) system and all of its cellular components are generated by hematopoietic stem cells (HSCs). However, when the DNA of these HSCs becomes mutated, normal blood development goes awry and a form of blood cancer termed leukemia may arise. In acute myeloid leukemia (AML) patients initially diagnosed respond well to chemotherapy and achieve remission (a state where little to no detectable disease remains), however, many patients die from a more aggressive relapse disease that later recurs. Thus, a better understanding of how mutated HSCs and the cells they produce, behave over the entire disease course is necessary to improve dismal patient outcomes.Recently it was shown that different types of rare stem-like cells that are already present at diagnosis, survive chemotherapy and regenerate relapse. I reason that these different stem cell types must use different biological mechanisms to escape therapy and reestablish disease. By extension, patients would benefit from tailoring their therapy to the type of relapse they will experience.In this proposal I aim to use state-of-the-art genetic and protein analysis tools to investigate patient samples over the entire disease course. The highly sensitive approach will reveal biological mechanisms and molecules (biomarkers) unique to each relapse type. Novel insights into relapse and the biomarkers generated will be used to predict relapse type from a diagnostic sample and to monitor patients during remission in order to inform the future of improved and personalized patient care.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Medeiros, Jessie J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~